Chandigarh Herald

Degenerative Disc Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Angitia Bio, Mesoblast

 Breaking News
  • No posts were found

Degenerative Disc Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Angitia Bio, Mesoblast

August 23
22:15 2023
Degenerative Disc Disease Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight | Angitia Bio, Mesoblast
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Degenerative Disc Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Degenerative Disc Disease Market.

 

The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Degenerative Disc Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Degenerative Disc Disease treatment therapies with a considerable amount of success over the years. 
  • Degenerative Disc Disease companies working in the treatment market are AnGes, Inc, Biosplice Therapeutics, Angitia Biopharmaceuticals, DiscGenics, Kuros Biosciences, BioRestorative Therapies, Mesoblast, Ltd., Spine Biopharma, Biosplice Therapeutics, Causeway Therapeutics, and others, are developing therapies for the Degenerative Disc Disease treatment 
  • Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are- AMG0103, SM04690, AGA111, IDCT, KUR 113, BRTX-100, Rexlemestrocel-L, SB 01, Lorecivivint, CWT 002, and others are expected to have a significant impact on the Degenerative Disc Disease market in the coming years.   
  • In January 2023, In order to develop and market a Notogen regenerative therapeutic that has the potential to be a first-in-class, disease-modifying treatment for people with degenerative disc disease (DDD), Notogen, Inc. recently announced that it had entered a worldwide research collaboration and licence agreement with Boehringer Ingelheim.
  • In November 2022, The PerQdiscTM Nucleus Replacement Device (NRD) LOPAIN2 clinical trial has begun, according to Spinal Stabilisation Technologies (SST). Patients without stenosis or instability who have degenerative disc disease (DDD) of the lumbar spine, which causes excruciating back pain, will be investigated with SST’s PerQdisc Nucleus Replacement Device. Using an anterior or lateral transpsoas approach, the PerQdisc is used for the surgical replacement of a single nucleus pulposus between the spinal lumbar discs L1-S1. For these people, there is currently no effective surgical alternative. PerQdisc NRD from SST is designed to relieve discogenic low back pain while preserving disc height and range of motion.
  • In August 2022, A Phase 3 multi-center, randomised, double-blind, placebo-controlled study to assess the safety and efficacy of SB-01 for injection in the treatment of lumbar degenerative disc disease was started by Spine BioPharma, Inc.
  • In April 2022, The degenerative disc medication developed by the South Korean pharmaceutical business Yuhan Corp. and licenced to an American pharmaceutical company will undergo a Phase 3 clinical study there. The U.S. Food and Drug Administration has granted Spine BioPharma permission to skip the second phase and enter the third phase of clinical testing for what it calls SB-01 in June.

 

Degenerative Disc Disease Overview

Back discomfort caused by or connected to intervertebral disc degeneration is referred to as degenerative disc disease (DDD). The intervertebral discs undergo a process in which they shrink and dehydrate. When this happens, the discs are unable to carry out their essential tasks of supplying movement and cushioning between the vertebrae.

 

Get a Free Sample PDF Report to know more about Degenerative Disc Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight

 

Emerging Degenerative Disc Disease Drugs Under Different Phases of Clinical Development Include:

  • AMG0103: AnGes, Inc
  • SM04690: Biosplice Therapeutics
  • AGA111: Angitia Biopharmaceuticals
  • IDCT: DiscGenics
  • KUR 113: Kuros Biosciences
  • BRTX-100: BioRestorative Therapies
  • Rexlemestrocel-L: Mesoblast, Ltd.
  • SB 01: Spine Biopharma
  • Lorecivivint: Biosplice Therapeutics
  • CWT 002: Causeway Therapeutics

 

Degenerative Disc Disease Route of Administration

Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Degenerative Disc Disease Molecule Type

Degenerative Disc Disease Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Degenerative Disc Disease Pipeline Therapeutics Assessment

  • Degenerative Disc Disease Assessment by Product Type
  • Degenerative Disc Disease By Stage and Product Type
  • Degenerative Disc Disease Assessment by Route of Administration
  • Degenerative Disc Disease By Stage and Route of Administration
  • Degenerative Disc Disease Assessment by Molecule Type
  • Degenerative Disc Disease by Stage and Molecule Type

 

DelveInsight’s Degenerative Disc Disease Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Degenerative Disc Disease product details are provided in the report. Download the Degenerative Disc Disease pipeline report to learn more about the emerging Degenerative Disc Disease therapies

 

Some of the key companies in the Degenerative Disc Disease Therapeutics Market include:

Key companies developing therapies for Degenerative Disc Disease are – Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others.

 

Degenerative Disc Disease Pipeline Analysis:

The Degenerative Disc Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Degenerative Disc Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Degenerative Disc Disease Treatment.
  • Degenerative Disc Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Degenerative Disc Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Degenerative Disc Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Degenerative Disc Disease drugs and therapies

 

Degenerative Disc Disease Pipeline Market Drivers

  • Increase in the prevalence of Degenerative Disc Disease, increasing Research and Development activities are some of the important factors that are fueling the Degenerative Disc Disease Market.

 

Degenerative Disc Disease Pipeline Market Barriers

  • However, cost associated with the treatment, poor patient compliance and other factors are creating obstacles in the Degenerative Disc Disease Market growth.

 

Scope of Degenerative Disc Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Degenerative Disc Disease Companies: AnGes, Inc, Biosplice Therapeutics, Angitia Biopharmaceuticals, DiscGenics, Kuros Biosciences, BioRestorative Therapies, Mesoblast, Ltd., Spine Biopharma, Biosplice Therapeutics, Causeway Therapeutics, and others
  • Key Degenerative Disc Disease Therapies: AMG0103, SM04690, AGA111, IDCT, KUR 113, BRTX-100, Rexlemestrocel-L, SB 01, Lorecivivint, CWT 002, and others
  • Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies
  • Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers 

 

Request for Sample PDF Report for Degenerative Disc Disease Pipeline Assessment and clinical trials

 

Table of Contents 

1. Degenerative Disc Disease Report Introduction

2. Degenerative Disc Disease Executive Summary

3. Degenerative Disc Disease Overview

4. Degenerative Disc Disease- Analytical Perspective In-depth Commercial Assessment

5. Degenerative Disc Disease Pipeline Therapeutics

6. Degenerative Disc Disease Late Stage Products (Phase II/III)

7. Degenerative Disc Disease Mid Stage Products (Phase II)

8. Degenerative Disc Disease Early Stage Products (Phase I)

9. Degenerative Disc Disease Preclinical Stage Products

10. Degenerative Disc Disease Therapeutics Assessment

11. Degenerative Disc Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Degenerative Disc Disease Key Companies

14. Degenerative Disc Disease Key Products

15. Degenerative Disc Disease Unmet Needs

16 . Degenerative Disc Disease Market Drivers and Barriers

17. Degenerative Disc Disease Future Perspectives and Conclusion

18. Degenerative Disc Disease Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services